Oova Alternatives: The Best Options for Every Use Case, Reviewed

What Is Oova and Is It Legit?

Oova is a direct-to-consumer urine hormone monitor that reads proprietary test strips with a smartphone camera and an AI algorithm to produce cycle-level hormone curves rather than a single-day positive or negative result. The platform tracks four analytes: luteinizing hormone (LH), follicle-stimulating hormone (FSH), pregnanediol glucuronide (PdG, the urine metabolite of progesterone), and estrone-3-glucuronide (E3G, the urine metabolite of estradiol).

The device is real. The hormones it measures are real. Whether the accuracy and clinical utility match the price is a harder question.

A 2021 company-funded study published by Oova's founding team reported a 96.7% concordance between Oova LH readings and reference immunoassay in a 37-participant sample. That number sounds strong, but the sample size is small, the study was not independently replicated, and 37 participants is far below the statistical bar most cleared-device accuracy studies use. An independent, peer-reviewed head-to-head trial against Mira, Clearblue, or serum LH does not yet exist in the published literature.

The framework that follows is built on four clinical use cases. Each use case maps to the hormone signal that actually matters, the evidence threshold a tool must clear to be useful, and which product wins on each dimension.

Is Oova FDA-cleared?

Oova's strips are manufactured under CLIA-equivalent quality standards and the company markets its device as a wellness product rather than an IVD diagnostic. It is not FDA-cleared as a diagnostic device, which means it cannot legally claim to diagnose infertility or confirm ovulation. The same limitation applies to Mira, Inito, and most consumer hormone monitors. Clearblue Advanced Digital Ovulation Test is FDA-cleared as an OTC ovulation predictor based on LH detection, which is a meaningful regulatory distinction if diagnostic accuracy matters to you.

Use Case 1: Trying to Conceive (Cycle Tracking and Ovulation Prediction)

For women actively trying to conceive, the goal of hormone tracking is narrow and precise: identify the fertile window (the five days before ovulation and the day of) with enough lead time to time intercourse or insemination. ASRM guidelines identify the LH surge, rising E2, and cervical mucus changes as the most practical markers of the fertile window in natural cycles.

What Oova gives you for TTC

Oova's four-hormone dashboard is genuinely more informative than a single-analyte LH strip. Seeing E3G rise before the LH surge gives you one to two extra days of warning. Seeing PdG rise post-ovulation gives you a rough confirmation that ovulation likely occurred, not just that an LH surge fired. For women with PCOS who have multiple LH surges per cycle, the fuller hormone picture may help distinguish a true fertile surge from a spurious one.

Where Oova falls short for TTC

The fertile window prediction is only as good as the algorithm. Oova's algorithm is trained on its own user data, and that dataset is not publicly described. Mira Fertility Plus, by contrast, quantifies LH in mIU/mL rather than a relative "low/high" flag, which mirrors how a reproductive endocrinologist actually reads a serum LH. A 2020 study in Fertility and Sterility found that quantitative urinary LH measurement (as Mira provides) improved ovulation detection sensitivity compared with qualitative threshold-based strips in women with PCOS.

Best TTC alternatives to Oova

| Need | Best option | Why | |---|---|---| | Budget-first | Clearblue Advanced Digital | FDA-cleared, large evidence base, ~$30-40/cycle | | Quantitative data | Mira Fertility Plus | Reports LH in mIU/mL, validated against serum | | TTC + post-ovulation confirmation | Inito | Tracks LH, E3G, PdG, FSH in one reader; app shows curves similar to Oova | | PCOS / irregular cycles | Mira or Inito | Quantitative LH reduces false-positive surge calls |

Use Case 2: PCOS and Irregular Cycles

PCOS affects 8-13% of reproductive-age women worldwide and is the leading cause of anovulatory infertility. Tracking ovulation in PCOS is genuinely harder than in eumenorrheic cycles. LH is often chronically elevated, the LH-to-FSH ratio may be skewed above 2:1, and cycles can stretch to 35-90 days.

Why standard LH strips mislead women with PCOS

A standard qualitative LH strip reads "positive" when LH crosses a fixed threshold, typically 25-40 mIU/mL. In PCOS, tonic LH is often already 20-35 mIU/mL at baseline, so a "positive" may appear on day 10, day 22, and day 38 of the same cycle with no true ovulation occurring. A 2003 study in Human Reproduction documented exactly this pattern, with 40% of PCOS cycles showing false-positive qualitative LH tests.

Oova's relative-change algorithm is designed to catch surges above an individual baseline rather than a population threshold. That is a meaningful design advantage. Mira's quantitative mIU/mL readout allows a similar approach: you learn your own tonic LH and identify a true surge as a rise of two to three times that baseline.

Practical recommendation for PCOS

Use a quantitative monitor (Mira or Inito) and pair it with basal body temperature tracking (BBT) confirmed by an app such as Tempdrop or Natural Cycles. BBT confirmation of ovulation requires a sustained temperature rise of at least 0.2°C for three consecutive mornings post-ovulation. The combination of quantitative LH plus BBT is more reliable than any single analyte alone, and costs less than Oova's monthly subscription.

Use Case 3: Perimenopause Hormone Monitoring

Perimenopause is where Oova's FSH measurement is most often marketed, and where the clinical picture is most complicated.

The promise: tracking FSH at home during the menopausal transition

FSH rises as ovarian reserve declines. The Menopause Society (formerly NAMS) describes perimenopause as a period of erratic and variable FSH, often swinging between normal and elevated values within the same cycle. Measuring FSH on one morning urine sample captures a single point in that variability, not a trend. A single elevated urine FSH does not confirm perimenopause. A single normal urine FSH does not rule it out.

What the evidence says about home FSH tests

A 2022 review in Menopause evaluated OTC FSH tests and concluded that a positive result (FSH above 25 IU/L) in a symptomatic woman has reasonable positive predictive value, but false-negative rates remain high in early perimenopause when FSH fluctuates. The authors explicitly stated the tests should not replace clinical evaluation.

Oova adds FSH to its curve visualization so you can see cycle-to-cycle FSH trends over weeks and months, not just one reading. That longitudinal view is more informative than a single First Response Menopause Test strip read on one morning. If you are experiencing hot flashes, cycle changes, or sleep disruption and you want a trend rather than a single answer, Oova's multi-cycle FSH tracking is a genuine improvement over single-use FSH strips.

Better alternatives for perimenopause depth

The DUTCH Complete test (Dried Urine Test for Comprehensive Hormones) measures estradiol, progesterone, testosterone, DHEA, cortisol, and their metabolites in a 24-hour urine sample collected at home and analyzed by a CLIA-certified lab. It is not a monitor. It is a lab test ordered through a clinician. It provides far more clinical depth than any consumer device, including Oova. Cost is $350-$500 and it requires a prescribing clinician. For women already experiencing moderate-to-severe perimenopausal symptoms, a DUTCH test plus an NAMS-certified menopause clinician consultation will give you more actionable data than any consumer monitor.

For women in the earlier stage of perimenopause who want self-directed monitoring between clinical visits, Oova's FSH trend tracking is a reasonable tool, with the explicit expectation that it informs questions to ask your clinician rather than replacing serum hormone testing.

Use Case 4: Postpartum and Breastfeeding Return of Fertility

Hormone tracking postpartum: what changes

Prolactin suppresses GnRH pulsatility during breastfeeding, which delays the return of LH surges and ovulation, sometimes for six to eighteen months. However, ovulation can precede the first postpartum period by two weeks, meaning a woman can conceive before she knows her cycle has returned.

Oova is not validated in the postpartum period. The company does not publish data on how its algorithm performs when baseline hormones are still suppressed by lactation. This is an evidence gap you should know about.

Inito has published a small feasibility study suggesting its multi-hormone reader can detect hormonal changes in postpartum cycles, though independent validation is still pending. For spacing pregnancies postpartum, the evidence-based approach remains the Lactational Amenorrhea Method (LAM) for the first six months (if fully breastfeeding, amenorrheic, and the infant is under six months), followed by a reliable contraceptive method as any of those conditions change.

No consumer hormone monitor replaces contraception postpartum.

Oova vs. Key Competitors: Head-to-Head

Oova vs. Mira Fertility Plus

Mira quantifies LH in mIU/mL and also tracks E3G, PdG, and FSH depending on the wand type you purchase. Its published analytical validation data includes a 2019 peer-reviewed study in JMIR mHealth showing correlation coefficients above 0.98 for urinary LH vs. Serum LH in 50 participants. That is a larger, more methodologically transparent dataset than Oova's published validation. Mira's subscription runs $45-$65/month for wands, similar to Oova's refill cost. The hardware reader is $199, slightly more than Oova's starter kit. For women prioritizing analytical rigor and quantitative output, Mira edges ahead.

Oova vs. Clearblue Advanced Digital

Clearblue Advanced Digital identifies two hormone changes (E3G and LH) and displays "High" (E3G rising) or "Peak" (LH surge) fertility. It is FDA-cleared, backed by decades of published ovulation-detection research, and costs approximately $35-$45 for a 20-count kit with no subscription. It does not track PdG or FSH. It does not show hormone curves. For women with regular cycles who want an evidence-based, affordable fertile window tool, Clearblue Advanced Digital remains the first-line recommendation in ACOG's optimizing natural fertility guidance.

Oova vs. Inito

Inito tracks the same four analytes as Oova (LH, E3G, PdG, FSH) and displays them as quantitative curves in its app. The reader attaches to a smartphone. A 2022 company-funded pilot in Fertility and Sterility Reports showed a 98.3% agreement with serum values for LH detection across 40 participants. Cost is approximately $99 for the reader and $49-$75/month for cartridges. Functionally, Oova and Inito are close rivals. Inito currently has slightly more published analytical data per analyte. The app experience and customer support differ, and user reviews on both are mixed for customer service responsiveness.

Oova vs. DUTCH Test

These serve different purposes. Oova is a real-time cycle monitor you use daily. DUTCH is a lab test you do once or twice a year to get a comprehensive snapshot of hormone metabolism. They are not in direct competition. A woman who wants to understand her hormone metabolites, cortisol rhythm, and estrogen detoxification pathways needs DUTCH. A woman who wants to time intercourse or watch her FSH trend monthly needs Oova or a similar monitor.

Who Should Use Oova and Who Should Not

Oova is a reasonable fit if you:

• Are in the early-to-mid stages of trying to conceive with mostly regular cycles (28-35 days)
• Have PCOS and want a relative-LH algorithm rather than a fixed threshold
• Are in early perimenopause and want to track FSH trends between clinical visits
• Are comfortable with a subscription cost and comfortable with limited independent validation data
• Want cycle data visualized as hormone curves rather than a simple positive/negative flag

Oova is likely not the right fit if you:

• Are on a tight budget (Clearblue Advanced Digital gives adequate fertile window prediction for a fraction of the cost)
• Need FDA-cleared diagnostic accuracy for a clinical decision
• Are postpartum or breastfeeding (no validation data in this state)
• Are in confirmed pregnancy (stop urine hormone monitoring)
• Have been trying to conceive for more than twelve months without success and need a clinical infertility workup rather than a consumer monitor. ACOG defines infertility as 12 months of unprotected intercourse without conception (or six months if you are over 35), and that threshold requires a clinician evaluation, not an upgraded monitor.

Pregnancy and Contraception: What You Need to Know

Oova is not a diagnostic pregnancy test. If you receive a positive pregnancy test (by standard hCG strip or digital test), stop urine hormone monitoring. Continuing LH and FSH tracking after confirmed conception provides no clinical value and the algorithm is not validated in the hormonal milieu of early pregnancy.

Oova is also not a contraceptive method. The fertile window it identifies should never be used as a family planning method to avoid pregnancy. Natural family planning methods based on hormone monitoring have typical-use failure rates of 2-23% per year depending on the method and user adherence, and consumer hormone monitors are not validated as contraceptive tools.

No hormone in Oova's panel is teratogenic. The device itself poses no exposure risk. The clinical concern is simpler: relying on any consumer monitor as contraception is not medically appropriate.

For women using fertility treatments (Clomid, letrozole, gonadotropins, or ART protocols), LH surge interpretation from a consumer device is unreliable because exogenous hormones distort the patterns the algorithm was trained on. Use serum monitoring under your reproductive endocrinologist's direction in those settings.

The Evidence Gap: What Is Not Yet Known

Women have been under-represented in device validation studies, and women with PCOS, perimenopause, and postpartum status are almost entirely absent from the published analytical validation data for every consumer hormone monitor on this list. That includes Oova, Mira, and Inito.

As WomanRx reviewer Dr. Elena Vasquez, MD, notes: "The consumer hormone monitor market has moved faster than the science. Every device you can buy today has company-funded validation data with sample sizes of 37-50 participants. None has a published RCT against serum hormone measurement in a diverse population of women across reproductive life stages. That does not make these tools useless. It means you use them to generate questions to bring to your clinician, not to replace the clinical conversation."

The honest bottom line is that no consumer urine hormone monitor has been validated in an independent, adequately powered clinical trial as of early 2025. The FDA's guidance on LH OTC devices does not require independent efficacy trials for OTC wellness monitors, only that labeling is not misleading. You are being asked to trust company-funded data at a $45-$75/month price point. That may be worth it for the qualitative value of hormone curve visualization and cycle literacy. Go in with that understanding.

Practical Decision Guide by Life Stage

Reproductive years, regular cycles, TTC under 6 months: Start with Clearblue Advanced Digital. If you want hormone curves or have PCOS, step up to Mira or Inito. Oova is a reasonable alternative at a similar price.

Reproductive years, PCOS, TTC: Use a quantitative monitor (Mira or Inito) plus BBT. Add a progesterone metabolite (PdG) measurement via monitor or a serum Day-21 progesterone from your OB-GYN to confirm ovulation actually occurred.

TTC over 12 months (or 6 months if over 35): See a reproductive endocrinologist. ASRM recommends a full infertility evaluation at this threshold. No consumer monitor substitutes for that evaluation.

Early perimenopause (irregular cycles, hot flashes, sleep disruption): Oova's FSH trend tracking adds some information between clinical visits. Pair it with a consultation with an NAMS-certified menopause clinician and serum FSH, estradiol, and TSH at least once per year.

Late perimenopause / confirmed menopause: Consumer hormone monitors are not designed for post-menopausal hormonal contexts. Focus on clinical hormone management, not at-home cycle tracking.

Postpartum / breastfeeding: No consumer hormone monitor is validated in this state. Use a reliable contraceptive method starting at three weeks postpartum per ACOG postpartum contraception guidance.